Denosumab: a case of MRONJ with resolution

descriptionPublicationkeyboard_double_arrow_right Article 24 Jun 2016 English Publisher:Springer Science and Business Media LLCJournal:British Dental Journal, volume 220, pages 623-625 (issn: 0007-0610, eissn: 1476-5373,

Copyright policy )

Authors: C V, Lyttle; H, Patterson;

doi: 10.1038/sj.bdj.2016.443

pmid: 27338901

Denosumab: a case of MRONJ with resolution

- Summary
- Subjects
- Metrics

Abstract

A patient was referred by a clinical oncologist regarding a non-healing area of bone in the lower jaw. The patient was taking denosumab (Prolia(®), Xgeva(®)) when they had a tooth extracted and the area failed to heal. Following suspension of the drug, the area healed with mucosal coverage. This new class of drugs are being increasingly used as an alternative antiresorptive drug to bisphosphonates and are licenced in the UK for prevention of osteoporotic fractures and prevention of skeletal-related events (SREs) in patients with metastatic cancer.

Keywords

Bone Density Conservation Agents, Diphosphonates, Jaw, Neoplasms, Tooth Extraction, Humans, Bisphosphonate-Associated Osteonecrosis of the Jaw, Denosumab, Aged

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	4
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average